Cerebrospinal fluid markers of neuronal and glial cell damage in patients with autoimmune neurologic syndromes with and without underlying malignancies.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Journal of Neuroimmunology

• Publication date

  2017-05-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.jneuroim.2017.02.018PMID 28385184
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cerebrospinal fluid markers of neuronal and glial cell damage to monitor disease activity and predict long‐term outcome in patients with autoimmune encephalitis

  2016cited by this paper
• A clinical approach to diagnosis of autoimmune encephalitis.

  2016cited by this paper
• CSF neurofilament light differs in neurodegenerative diseases and predicts severity and survival

  2014cited by this paper
• Positivity of serum "classical" onconeural antibodies in a series of 2063 consecutive patients with suspicion of paraneoplastic neurological syndrome.

  2013cited by this paper
• The diagnosis and treatment of limbic encephalitis

  2012cited by this paper
• Central nervous system neuronal surface antibody associated syndromes: review and guidelines for recognition

  2012cited by this paper
• Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis.

  2011cited by this paper
• Screening for tumours in paraneoplastic syndromes: report of an EFNS Task Force

  2011cited by this paper
• Cerebrospinal fluid and plasma biomarkers in Alzheimer disease

  2010cited by this paper
• Cerebrospinal fluid study in paraneoplastic syndromes

  2009cited by this paper
• Paraneoplastic syndromes of the CNS.

  2008cited by this paper
• Neuronal surface antigen antibodies in limbic encephalitis

  2008cited by this paper
• Paraneoplastic neurological syndromes: diagnosis and treatment

  2007cited by this paper
• Recommended diagnostic criteria for paraneoplastic neurological syndromes

  2004cited by this paper
• Elevated neurofilament levels in neurological diseases.

  2003cited by this paper
• Paraneoplastic syndromes involving the nervous system.

  2003cited by this paper
• Sub‐acute cerebellar degeneration with anti‐Yo autoantibodies: immunohistochemical analysis of the immune reaction in the central nervous system

  1997cited by this paper
• Protein Analysis in Cerebrospinal Fluid

  1993cited by this paper
• Protein analysis in cerebrospinal fluid. II. Reference values derived from healthy individuals 18-88 years of age.

  1993cited by this paper
• The use of the Karnofsky Performance Scale in determining outcomes and risk in geriatric outpatients.

  1991cited by this paper
• The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results.

  1991cited by this paper
• Cerebral Vascular Accidents in Patients over the Age of 60: II. Prognosis

  1957cited by this paper

• Associations Between Malignant Tumors and Alzheimer's Disease: A Cross‐Sectional Study

  2025cites this paper
• Dermatomyositis-Related Encephalopathy: Clinical, Neuroimaging and Immunological Characterization

  2025cites this paper
• Neuroglial biomarkers in autoimmune encephalitis: advances in diagnosis, prognosis, and pathophysiological insights

  2025influential citation
• Phenotypic and oncological insights in ANNA1 autoimmunity: Age stratification and biomarker analysis

  2024cites this paper
• Predictive Value of Serum Neurofilament Light Chain Levels in Anti-NMDA Receptor Encephalitis

  2023cites this paper
• Neural Surface Antibodies and Neurodegeneration: Clinical Commonalities and Pathophysiological Relationships

  2023influential citation
• Cerebrospinal fluid YKL‐40 level evolution is associated with autoimmune encephalitis remission

  2023influential citation
• Drug-resistant epilepsy at the age extremes: Disentangling the underlying etiology.

  2022cites this paper
• The Use of Real-Time Quaking-Induced Conversion for the Diagnosis of Human Prion Diseases

  2022cites this paper
• Evaluation of Plasma Neurofilament Light Chain Levels as a Biomarker of Neuronal Injury in the Active and Chronic Phases of Autoimmune Neurologic Disorders

  2022cites this paper
• Neuronal and Neuroaxonal Damage Cerebrospinal Fluid Biomarkers in Autoimmune Encephalitis Associated or Not with the Presence of Tumor

  2022cites this paper
• Autoimmune Encephalitis and Autism Spectrum Disorder

  2021cites this paper
• Clinical and Prognostic Value of Immunogenetic Characteristics in Anti-LGI1 Encephalitis

  2021cites this paper
• Cerebrospinal Fluid and Blood Neurofilament Light Chain Protein in Prion Disease and Other Rapidly Progressive Dementias: Current State of the Art

  2021cites this paper
• Autoimmune Encephalitis in Late-Onset Seizures: When to Suspect and How to Treat

  2021cites this paper
• Core cerebrospinal fluid biomarker profile in anti-LGI1 encephalitis

  2021cites this paper
• Current Nosology of Neural Autoantibody-Associated Dementia

  2021cites this paper
• Neuronal damage and neuroinflammation markers in patients with autoimmune encephalitis and multiple sclerosis

  2019cites this paper
• Serum and CSF neurofilament light chain levels in antibody-mediated encephalitis

  2019cites this paper
• Autoimmune Dementia

  2018cites this paper
• Treatment with the monoclonal antibody rituximab in Multiple Sclerosis : a study based on an academic clinical trial

  2018influential citation
• Autoimmune Encephalitis - A comparison of patients with anti-GAD and anti-NMDAR antibodies

  2017cites this paper
• Diagnostic des encéphalites auto-immunes

  2012cites this paper